Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Vaccinex, Inc is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccinex employs 39 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $2.34 |
|---|---|
| 52-week range | $1.63 - $7.20 |
| 50-day moving average | $2.60 |
| 200-day moving average | $2.77 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.01 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.34 from 2021-05-26
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | -14.60% |
| 3 months (2021-05-05) | -1.27% |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Revenue TTM | $1.5 million |
|---|---|
| Gross profit TTM | $-20,926,000 |
| Return on assets TTM | -96.35% |
| Return on equity TTM | -268.76% |
| Profit margin | 0% |
| Book value | $0.03 |
| Market capitalisation | $69.7 million |
TTM: trailing 12 months
There are currently 830,358 Vaccinex shares held short by investors – that's known as Vaccinex's "short interest". This figure is 9.1% down from 913,296 last month.
There are a few different ways that this level of interest in shorting Vaccinex shares can be evaluated.
Vaccinex's "short interest ratio" (SIR) is the quantity of Vaccinex shares currently shorted divided by the average quantity of Vaccinex shares traded daily (recently around 247130.35714286). Vaccinex's SIR currently stands at 3.36. In other words for every 100,000 Vaccinex shares traded daily on the market, roughly 3360 shares are currently held short.
However Vaccinex's short interest can also be evaluated against the total number of Vaccinex shares, or, against the total number of tradable Vaccinex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaccinex's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Vaccinex shares in existence, roughly 30 shares are currently held short) or 0.0537% of the tradable shares (for every 100,000 tradable Vaccinex shares, roughly 54 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaccinex.
Find out more about how you can short Vaccinex stock.
We're not expecting Vaccinex to pay a dividend over the next 12 months.
Over the last 12 months, Vaccinex's shares have ranged in value from as little as $1.63 up to $7.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccinex's is 1.752. This would suggest that Vaccinex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Vaccinex, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
